The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial
Abstract
IMPORTANCE: Global use of human papillomavirus (HPV) vaccines to prevent cervical cancer is impeded by cost. A 2-dose schedule for girls may be possible. OBJECTIVE: To determine whether mean antibody levels to HPV-16 and HPV-18 among girls receiving 2 doses was noninferior to women receiving 3 doses. DESIGN, SETTING, AND PATIENTS: Randomized, phase 3, postlicensure, multicenter, age-stratified, noninferiority immunogenicity study of 830 Canadian females from August 2007 through February 2011. Follow-up blood samples were provided by 675 participants (81%). INTERVENTION: Girls (9-13 years) were randomized 1:1 to receive 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261) or 2 doses at 0 and 6 months (n = 259). Young women (16-26 years) received 3 doses at 0, 2, and 6 months (n = 310). Antibody levels were measured at 0, 7, 18, 24, and 36 months. MAIN OUTCOMES AND MEASURES: Primary outcome was noninferiority (95% CI, lower bound >0.5) of geometric mean titer (GMT) ratios for HPV-16 and HPV-18 for girls (2 doses) compared with young women (3 doses) 1 month after last dose. Secondary outcomes were noninferiority of GMT ratios of girls receiving 2 vs 3 doses of vaccine; and durability of noninferiority to 36 months. RESULTS: The GMT ratios were noninferior for girls (2 doses) to women (3 doses): 2.07 (95% CI, 1.62-2.65) for HPV-16 and 1.76 (95% CI, 1.41-2.19) for HPV-18. Girls (3 doses) had GMT responses 1 month after last vaccination for HPV-16 of 7736 milli-Merck units per mL (mMU/mL) (95% CI, 6651-8999) and HPV-18 of 1730 mMU/mL (95% CI, 1512-1980). The GMT ratios were noninferior for girls (2 doses) to girls (3 doses): 0.95 (95% CI, 0.73-1.23) for HPV-16 and 0.68 (95% CI, 0.54-0.85) for HPV-18. The GMT ratios for girls (2 doses) to women (3 doses) remained noninferior for all genotypes to 36 months. Antibody responses in girls were noninferior after 2 doses vs 3 doses for all 4 vaccine genotypes at month 7, but not for HPV-18 by month 24 or HPV-6 by month 36. CONCLUSIONS AND RELEVANCE: Among girls who received 2 doses of HPV vaccine 6 months apart, responses to HPV-16 and HPV-18 one month after the last dose were noninferior to those among young women who received 3 doses of the vaccine within 6 months. Because of the loss of noninferiority to some genotypes at 24 to 36 months in girls given 2 doses vs 3 doses, more data on the duration of protection are needed before reduced-dose schedules can be recommended. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00501137.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.001 · Cited by 2,345
Chapter 1: HPV in the etiology of human cancer
Muñoz, N., Castellsagué, X., de González, A. B., & Gissmann, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.115 · Cited by 1,355
Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603469 · Cited by 806
Block, S. L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K. E. D., Marchant, C. D., Castellsagué, X., Rusche, S. A., Lukac, S., Bryan, J. T., et al. (2006) · Pediatrics · doi:10.1542/peds.2006-0461 · Cited by 484
Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L. R., Petta, C. A., Andrade, R. P., Brown, D. R., Ferenczy, A., Harper, D. M., Koutsky, L. A., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.068 · Cited by 469
Olsson, S.-E., Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Malm, C., Iversen, O.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.049 · Cited by 454
Kreimer, A. R., Rodriguez, A. C., Hildesheim, A., Herrero, R., Porras, C., Schiffman, M., González, P., Solomon, D., Jiménez, S., Schiller, J. T., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr319 · Cited by 324
Reisinger, K. S., Block, S. L., Lazcano-Ponce, E., Samakoses, R., Esser, M. T., Erick, J., Puchalski, D., Giacoletti, K. E. D., Sings, H. L., Lukac, S., et al. (2007) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000253970.29190.5a · Cited by 296
Opalka, D., Lachman, C. E., MacMullen, S. A., Jansen, K. U., Smith, J. F., Chirmule, N., & Esser, M. T. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.1.108-115.2003 · Cited by 276
Dias, D., Van Doren, J., Schlottmann, S., Kelly, S., Puchalski, D., Ruiz, W., Boerckel, P., Kessler, J., Antonello, J. M., Green, T., et al. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.8.959-969.2005 · Cited by 241
(2011) · PubMed · Cited by 229
Romanowski, B., Schwarz, T. F., Ferguson, L. M., Peters, K., Dionne, M., Schulze, K., Ramjattan, B., Hillemanns, P., Catteau, G., Dobbelaere, K., et al. (2011) · Human Vaccines · doi:10.4161/hv.7.12.18322 · Cited by 194
Self-citationDessy, F. J., Giannini, S. L., Bougelet, C. A., Kemp, T. J., David, M.-P. M., Poncelet, S. M., Pinto, L. A., & Wettendorff, M. A. (2008) · Human Vaccines · doi:10.4161/hv.4.6.6912 · Cited by 179
Evaluation of OPV and polio eradication
Arya, S. C. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.07.047 · Cited by 171
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Day, P. M., Kines, R. C., Thompson, C. D., Jagu, S., Roden, R. B., Lowy, D. R., & Schiller, J. T. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.08.003 · Cited by 171
Java Applets for Power and Sample Size
Lenth, R. V. (2018) · QUBES · doi:10.25334/q4m71q · Cited by 165
Longet, S., Schiller, J. T., Bobst, M., Jichlinski, P., & Nardelli‐Haefliger, D. (2011) · Journal of Virology · doi:10.1128/jvi.06093-11 · Cited by 117
Brown, D. R., Garland, S. M., Ferris, D. G., Joura, E. A., Steben, M., James, M. K., Radley, D. R., Vuocolo, S. C., Garner, E. I. O., Haupt, R. M., et al. (2011) · Human Vaccines · doi:10.4161/hv.7.2.13948 · Cited by 112
Cassidy, W. M., Watson, B. M., Ioli, V. A., Williams, K., Bird, S. R., & West, D. J. (2001) · PEDIATRICS · doi:10.1542/peds.107.4.626 · Cited by 109
Smolen, K. K., Gelinas, L., Franzén, L., Dobson, S., Dawar, M., Ogilvie, G. S., Krajden, M., Fortuno, E. S., & Kollmann, T. R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.051 · Cited by 69
Self-citationKrajden, M., Cook, D. A., Yu, A., Chow, R., Mei, W., McNeil, S., Money, D., Dionne, M., Karunakaran, K. P., Palefsky, J. M., et al. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00489-10 · Cited by 59
Self-citationStatistical Considerations for NonInferiority/Equivalence Trials in Vaccine Development
Wang, W. W. B., Mehrotra, D. V., Chan, I. S. F., & Heyse, J. F. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600719251 · Cited by 41
Cited by
Cervical cancer: A global health crisis
Small, W., Bacon, M. A., Bajaj, A., Chuang, L. T., Fisher, B. J., Harkenrider, M. M., Jhingran, A., Kitchener, H. C., Mileshkin, L. R., Viswanathan, A. N., et al. (2017) · Cancer · doi:10.1002/cncr.30667 · Cited by 1,168
Carcinogenic human papillomavirus infection
Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.86 · Cited by 999
Meites, E., Kempe, A., & Markowitz, L. E. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6549a5 · Cited by 802
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., Brawley, O. W., & Wender, R. C. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21392 · Cited by 719
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Metadata
- Authors
- Dobson, S. R. M., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., Sauvageau, C., Scheifele, D. W., Kollmann, T. R., Halperin, S. A., Langley, J. M., Bettinger, J. A., Singer, J., Money, D., Miller, D., Naus, M., Marra, F., & Young, E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-05-01
- Volume
- 309
- Issue
- 17
- Pages
- 1793
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2014164721
- Cited by
- 417
- References
- 24
- FWCI
- 41.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.